In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk. Pisetsky DS. Ann Intern Med 2023;176:JC5.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pisetsky DS. In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk. Ann Intern Med 2023;176:JC5.
PMID: 36592464